An investigation on behalf of investors of Vaccinex, Inc. (NASDAQ: VCNX) shares over potential securities laws violations by Vaccinex, Inc. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Vaccinex, Inc. (NASDAQ: VCNX) concerning whether a series of statements by Vaccinex, Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Rochester, NY based Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. On August 9, 2018, Vaccinex, Inc. announced the pricing for its initial public offering. Vaccinex, Inc sold 3.33 million shares at $12.00 per share. Since then shares of Vaccinex, Inc. (NASDAQ: VCNX) declined to as low as $3.94 per share on July 26, 2019.